Radical Prostatectomy For Prostatic Adenocarcinoma: Matched Comparison Of Retropubic And Robot Assisted Techniques
Main Category: Prostate / Prostate CancerAlso Included In: Urology / Nephrology
Article Date: 22 Jun 2008 - 0:00 PDT
| Patient / Public: | ![]() |
5 (2 votes) |
| Healthcare Prof: | ![]() |
ORLANDO, FL (UroToday.com) - A group of investigators from the Mayo Clinic assessed peri-operative complications and early oncologic results in a comparative study matching radical retropubic (RRP) and robot assisted laparoscopic prostatectomy (RALP) groups.
From August 2002 and December 2005, they identified 294 patients undergoing RALP for clinically localized prostate cancer. A comparison RRP group (n=588) from the same period was matched 2:1 for surgical year, age, preoperative PSA, clinical stage and biopsy Gleason grade. Peri-operative complications were compared. Pathologic features were assessed and Kaplan-Meier estimates of biochemical progression free survival (PFS) were compared.
Peri-operative complications were higher in the RALP group (16.4% vs. 9.8%, p = 0.007), of which extravasation on cystogram was more common in the RALP group, (9.1% vs. 2.5%, p<0.001). Hospital days were less for the RALP cohort (29.3%, vs. 19.4%, p=0.004, for 1 hospital day). Differences in age, preoperative PSA, pathologic stage, pathologic Gleason grade and margin positivity were not significant between the 2 groups. At one year follow-up there was no significant difference in continence (RALP 91.8%, RRP 93.7%, p=0.344) or potency (RALP 70.0%, RRP 62.8%, p=0.081) rates between the two groups. Three-year biochemical PFS was not different among treatment options (RALP 92.4%, RRP 92.2%; p=0.69).
They conclude that RALP was associated with significantly higher early complication rates compared to RRP; however, there was no difference in long-term continence or potency rates between the two techniques. Furthermore, early oncologic outcomes were similar with no difference in margin positivity or short-term PFS between the two groups.
Presented by Amy E Krambeck, MD, David S DiMarco, MD, Laureano J Rangel, MD, Eric J Bergstralh, MD, Michael L Blute, MD, Matthew T Gettman, MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.
Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
Copyright © 2008 - UroToday
Visit our prostate / prostate cancer section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/112292.php>
APA
http://www.medicalnewstoday.com/releases/112292.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




